Genome-scale integration of transcriptome and metabolome unveils squalene synthase and dihydrofolate reductase as targets against AML cells resistant to chemotherapy

The development of resistance to chemotherapeutic agents, such as Doxorubicin (DOX) and cytarabine (AraC), is one of the greatest challenges to the successful treatment of Acute Myeloid Leukemia (AML). Such acquisition is often underlined by a metabolic reprogramming that can provide a therapeutic o...

Descripción completa

Detalles Bibliográficos
Autores principales: Karakitsou, Effrosyni, Foguet, Carles, Contreras Mostazo, Miriam G., Kurrle, Nina, Schnütgen, Frank, Michaelis, Martin, Cinatl, Jindrich, Marin, Silvia, Cascante, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326745/
https://www.ncbi.nlm.nih.gov/pubmed/34377370
http://dx.doi.org/10.1016/j.csbj.2021.06.049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326745/
https://www.ncbi.nlm.nih.gov/pubmed/34377370
http://dx.doi.org/10.1016/j.csbj.2021.06.049

Ejemplares similares